Hepatitis C Management in Special Populations

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 8/17/18 (What's New)

Summary

  • The AASLD/IDSA guidelines recommend that children with chronic HCV infection who are older than 3 years of age should receive treatment with DAA regimens, if available for the child’s age group[AASLD-IDSA HCV]
    • Treatment of children 3-11 years of age with chronic HCV infection should be deferred until interferon-sparing regimens are available for their age group
  • Ledipasvir/sofosbuvir and sofosbuvir plus ribavirin are the first direct-acting antivirals approved by the FDA for the treatment of HCV infection in patients 12-17 years of age

    Action required